Home
OE Originals
OE Insights
CME
All Specialties
Arthroplasty
Cannabis
Ev. Based Medicine
Foot & Ankle
General Orthopaedics
Hand & Wrist
Metabolic Disorders
Osteoarthritis
Pediatric Orthopaedics
Peri-Operative
Phys. Therapy & Rehab
Shoulder & Elbow
Spine
Sports Medicine
Trauma
Tumour

Author Interviews

Conference Reports

PeerView

All Videos
(199 Videos)

Leadership
(1 Videos)
Research
(1 Videos)
OrthoJoe
(63 Videos)
Webinar
(9 Videos)
OE Headline
(7 Videos)
OrthoPod
(117 Videos)

COVID-19 Resource Center

OE World Tour

OE Perspectives

OE Ideas

OE Recommends

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover
Tumour

Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
August 2013
Tumour High Impact Icon

Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival

Vol: 2| Issue: 7| Number:613| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095

Contributing Authors:
PA Meyers CL Schwartz MD Krailo JH Healey ML Bernstein D Betcher WS Ferguson MC Gebhardt AM Goorin M Harris E Kleinerman MP Link H Nadel M Nieder GP Siegal MA Weiner RJ Wells RB Womer HE Grier Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

OE EXCLUSIVE

Dr. Paul A. Meyers discusses the addition of muramyl tripeptide to chemotherapy in the treatment of Osteosarcoma.

Synopsis

662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year evaluations of event free survival (...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
Ace Report Preview Image
CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue